GenMont — Annual Report 2021

Dec 23, 2021

==> picture [407 x 54] intentionally omitted <==

==> picture [437 x 64] intentionally omitted <==

GenMont Biotech Incorporation The leading brand of functional probiotics

葉天佑 協理 Alvin Yeh Senior Manager

1

1

益生菌市場前景

==> picture [301 x 9] intentionally omitted <==

Probiotics market outlook

==> picture [15 x 8] intentionally omitted <==

==> picture [16 x 8] intentionally omitted <==

==> picture [16 x 8] intentionally omitted <==

 全球益生菌市場正在快速成長 The global probiotics market is growing rapidly. 其成長的主要原因是消費者對於預防保健的意識提升 The major factor boosting the market growth is increasing concerns of consumers on preventive healthcare.

 中國大陸仍為臺灣食品的重要出口國 China is still an important exporter of Taiwanese food.  後疫情時代來臨，人們更積極尋求維持健康的方法 Beyond the pandemic, people have more conscious about their health and are taking proactive measures to help maintain their well-being.

隨著 COVID-19 疫情蔓延，消費者對機能性食品的長期需求增加 As the COVID-19 pandemic wears on, it increased the long-term demand for functional food/beverages and supplements in the daily behavior of consumers.

資料來源： Functional Food & Beverage 2020 Report Highlights from the Hartman Group

2

全球益生菌市場快速發展

==> picture [469 x 9] intentionally omitted <==

Global probiotics market is growing rapidly

全球市場分析報告顯示， 。 預計 2026 年全球益生菌市場約為 911 億美元

The global market analysis report shows that the global probiotic market is expected to be about 91.1 billion US dollars in 2026.

全球益生菌市場應用 Global probiotics market by product application

Global Probiotics Market

* 市場分布 MARKET SHARE** 功能性食品 Functional food

==> picture [338 x 195] intentionally omitted <==

----- Start of picture text -----

Market forecast to grow at a CAGR of 8.3%
USD 91.1 Billion
USD 61.1 Billion
e-Estimated;
2021-e 2026-p p-Projected
----- End of picture text -----

保健食品與藥品 Health food and medicine 益生菌原料 Probiotics raw material

==> picture [195 x 198] intentionally omitted <==

資料來源：

https://www.reportlinker.com/p05129364/Probiotics-Market-by-Application-Dietary-SupplementsAnimal-Feed-Source-Form-End-User-And-Region-Forecast-to.html?utm_source=GNW; https://www.researchandmarkets.com/reports/5370159/global-probiotics-market-by-application

3

口 中國大陸為臺灣食品重要出 對象

==> picture [638 x 9] intentionally omitted <==

China is an important export target of Taiwanese food

==> picture [353 x 327] intentionally omitted <==

==> picture [104 x 325] intentionally omitted <==

單位 : 新臺幣 ( 億元 ) 出口 1053 億元 占總產值 18.7%

資料來源 : IT IS 智網，食品所 IT IS 團隊分析整理 (2021/06)

4

2021 年度研究成果介紹 The Annual Research Presentation 2021

5

158 項研發專利

Patents over the world

==> picture [700 x 384] intentionally omitted <==

----- Start of picture text -----

日本 JP 澳洲 AU Allergy
9 1 Obesity 治療過敏
8 Cardiac Inflammation
治療肥胖
美國 US 心臟發炎
臺灣 TW Others 3
6
26
50 其他 Autoimmune Diseases
中國 CN H. Pylori 35 自體免疫疾病
30 歐洲 42 EP 抗幽門桿菌 infection Anti-stroke 中風 5 Oral Health
3
4 口腔保健
10
Hypertension
血壓 Picornavirus infection
2 抗腸病毒
3
Blood lipid
Atopic dermatitis
血脂
Wound healing 傷口癒合 3 異位性皮膚炎
& scar care 疤痕護理 6
2 Diabetes
Skin Care 皮膚護理 Psoriasis 糖尿病
3 乾癬 17
4 Weight Control
控制體重
Osteoporosis 骨鬆 4
6
Anti-inflammatory
Pancreatic cancer C. difficile Underarm 抗發炎
胰臟癌 infection Stability odour 10
4 改善
改善困難梭狀 安定性 Vaginal Care 護肝 Liver Care
狐臭
桿菌感染 ( 新型 ) 女性保健 2
4
4 3 7
----- End of picture text -----

6

44 篇文獻發表

Published Papers

==> picture [647 x 410] intentionally omitted <==

----- Start of picture text -----

Safety
Vaginal Care 安全 其他 Others
女性保健 2 2
Skin Care 1
皮膚護理
Allergy
2 過敏
Animal Health 12
動物用益生菌
1
Pancreatic cancer
胰臟癌
2 Asthma
Autoimmune 氣喘
自體免疫疾病
1
4
Anti H. pylori Immunoregulation
抗幽門螺旋桿菌 免疫調節
1 1
Atopic dermatitis
Psoriasis
異位性皮膚炎
乾癬
1
1 Dental health 血糖 Blood sugar
牙齒
3
2 代謝 Metabolism 血脂 Blood lipid
2 6
7
----- End of picture text -----

7

8

==> picture [228 x 207] intentionally omitted <==

==> picture [86 x 54] intentionally omitted <==

==> picture [150 x 29] intentionally omitted <==

==> picture [52 x 73] intentionally omitted <==

==> picture [49 x 73] intentionally omitted <==

==> picture [49 x 72] intentionally omitted <==

==> picture [48 x 71] intentionally omitted <==

==> picture [56 x 74] intentionally omitted <==

==> picture [49 x 71] intentionally omitted <==

==> picture [48 x 71] intentionally omitted <==

==> picture [52 x 70] intentionally omitted <==

TW I 678209B US 10632160 B2 ZL 2018 1 0244949.4 IT 102019000004185 TW I 346554B US 7901926 B2 EP 2287286 B1 ZL 2010 1 0567585.7

==> picture [86 x 58] intentionally omitted <==

==> picture [115 x 139] intentionally omitted <==

==> picture [229 x 120] intentionally omitted <==

==> picture [158 x 141] intentionally omitted <==

運用K-ras[G12D] 基因轉殖小 鼠的胰臟癌動物模式證 實，乳酸桿菌可減弱胰臟 癌惡化

==> picture [299 x 185] intentionally omitted <==

==> picture [85 x 22] intentionally omitted <==

==> picture [197 x 69] intentionally omitted <==

基因轉殖胰臟癌動物模式證 實，乳酸桿菌合併化療藥物 (Gemcitabine)使用，可發揮抑 制癌細胞生長的協同作用

8

Financial status 財務狀況

==> picture [186 x 9] intentionally omitted <==

==> picture [236 x 9] intentionally omitted <==

- ※母公司財報 景岳生技 Separate Financial Statements-GenMont

單位：千元 In Thousands of New Taiwan Dollars	107年母公司財報 (Year 2018 Single)	108年母公司財報 (Year 2019 Single)	109年母公司財報 (Year 2020 Single)
營業收入NET REVENUE	406,554	346,244	325,191
營業毛利GROSS PROFIT	277,547	229,701	215,390
營業費用OPERATING EXPENSES	(152,245)	(148,838)	(137,605)
營業利益INCOME(LOSS) FROM OPERATIONS	125,302	80,863	77,785
營業外損益NON- OPERATING INCOME AND EXPENSES	58,522	(5,107)	(269)
稅前淨利INCOME(LOSS) BEFORE INCOME TAX	183,824	75,756	77,516
稅後淨利NET INCOME(LOSS)	158,019	57,451	60,884

9

Financial status 財務狀況

==> picture [186 x 9] intentionally omitted <==

==> picture [236 x 9] intentionally omitted <==

※ 合併財報 Consolidated Financial Statements

單位：千元 In Thousands of New Taiwan Dollars	108年合併 (Year 2019 Consolidated)	109年合併 (Year 2020 Consolidated)	110年前三季合併 (Year 2021 Q3 Consolidated)
營業收入NET REVENUE	346,244	**325,191 **	308,608
營業毛利GROSS PROFIT	229,701	215,390	215,052
營業費用OPERATING EXPENSES	(152,078)	(144,376)	(125,787)
營業利益INCOME(LOSS) FROM OPERATIONS	77,623	71,014	89,265
營業外損益NON-OPERATING INCOME AND EXPENSES	(2,083)	5,833	**(2,109) **
稅前淨利INCOME(LOSS) BEFORE INCOME TAX	75,540	76,847	87,156
稅後淨利NET INCOME(LOSS)	57,235	60,215	66,483
停業單位損益Income (Loss)from Discountinued Operations	0	0	0
本期淨利NET INCOME(LOSS)	57,235	60,215	66,483

10

營業收入 NET REVENUE

==> picture [275 x 8] intentionally omitted <==

==> picture [288 x 200] intentionally omitted <==

----- Start of picture text -----

單位：千元
450000
400000
350000
300000
250000
200000
150000
100000
50000
0
2019 2020 2021 Q1~Q3
----- End of picture text -----

淨利 NET INCOME

==> picture [211 x 8] intentionally omitted <==

單位：千元

==> picture [286 x 189] intentionally omitted <==

----- Start of picture text -----

80000
70000
60000
50000
40000
30000
20000
10000
0
2019 2020 2021 Q1~Q3
----- End of picture text -----

11

Risk Assessment 風險評估

生技領域方面財務風險 Financial risk in the biotech sector • 研發期間長 Long R & D period

• 獲利回收晚 Late profit recovery

， 可能因此導致資金不足 Which may lead to insufficient funds

益生菌市場持續成長 Probiotics market continues to grow 在人體腸道微生物組的開拓下，使全球許多消費者都意識到益生菌菌株 對人體的健康和免疫的影響，挑選益生菌產品的基準也從「益生菌」轉 移到菌株的功能性上。根據 Frost & Sullivan 的推估，乳酸桿菌年複合成 。 長率為 5.8%

With the development of the human gut microbiome, many consumers around the world are aware of the effects of probiotic strains on human health and immunity. The criteria for selecting probiotic products has also shifted from "probiotics" to the functionality of the strains. According to Frost & Sullivan's estimation, Lactobacillu s will grow with a compound annual growth rate of 5.8%

==> picture [255 x 159] intentionally omitted <==

資料來源 : 食品工業發展研究所 / 食品產業知識庫 /https://member.frost.com/landing/home ,2021/10/04]

12

==> picture [257 x 159] intentionally omitted <==

Thanks For Your Attention

==> picture [349 x 99] intentionally omitted <==

----- Start of picture text -----

Q & A
----- End of picture text -----

13